Active substance
Results for the substance daratumumab
2 results
About this active substance
Daratumumab is a monoclonal antibody used for the treatment of multiple myeloma, a type of cancer affecting plasma cells. It works by binding to the CD38 protein on the surface of cancer cells, stimulating the immune system to destroy them.
The medication is administered via intravenous infusion or subcutaneously and is often used in combination with other drugs to enhance treatment effectiveness. It is indicated for patients with relapsed or refractory multiple myeloma.
Side effects may include fatigue, nausea, respiratory infections, and infusion-related reactions. Close monitoring is essential to manage potential complications.
Consult your doctor to discuss the benefits and risks of treatment with Daratumumab. This medication must be administered under the supervision of an oncology specialist.
The medication is administered via intravenous infusion or subcutaneously and is often used in combination with other drugs to enhance treatment effectiveness. It is indicated for patients with relapsed or refractory multiple myeloma.
Side effects may include fatigue, nausea, respiratory infections, and infusion-related reactions. Close monitoring is essential to manage potential complications.
Consult your doctor to discuss the benefits and risks of treatment with Daratumumab. This medication must be administered under the supervision of an oncology specialist.